This segment focuses on the development of Navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, currently in Phase 3 clinical trials. Research and development activities are centered on optimizing the drug's efficacy and safety profile for HAE patients. The therapeutic target is to reduce the frequency and severity of angioedema attacks, improving the quality of life for individuals with this rare genetic condition. The market positioning involves competing with existing HAE treatments by offering a potentially more convenient and effective prophylactic option. Future opportunities include expanding the drug's application to other kallikrein-mediated diseases and securing regulatory approvals in key global markets. Clinical trials are conducted in accordance with regulatory guidelines to ensure patient safety and data integrity.

This segment is dedicated to the development of STAR-0310, a monoclonal antibody OX40 antagonist, currently in preclinical development for the treatment of atopic dermatitis. Research efforts are focused on understanding the role of OX40 in the pathogenesis of atopic dermatitis and developing a targeted therapy to reduce inflammation and itching. The therapeutic goal is to restore skin barrier function and alleviate the symptoms of this chronic immune disorder. The market positioning involves competing with existing topical and systemic treatments for atopic dermatitis by offering a potentially more targeted and effective biologic therapy. Future opportunities include advancing STAR-0310 into clinical trials and exploring its potential in other OX40-mediated inflammatory diseases. Preclinical studies are conducted to assess the drug's safety and efficacy before initiating human trials.